New Drugs Take Center Stage as Biogen Heads Into Q4 Earnings

Key Takeaways BIIB will report Q4 results on Feb. 6, with consensus estimate for sales at $2.21B & EPS at $1.60 per share.Biogen faces MS drug declines from generics, but Vumerity, Skyclarys and Zurzuvae can show growth.BIIB's Alzheimer's revenues may have risen as U.S. Leqembi sales improve.Biogen (BIIB) will report fourth-quarter and full-year 2025 results on Feb. 6, before market open. In the last reported quarter, the company's earnings beat expectations by 23.65%. The Zacks Consensus Estimate for fourt ...